ACA Marketplace Plans

How ACA Marketplace Plans approaches GLP-1 coverage

ACA Marketplace plans (Bronze, Silver, Gold, Platinum) sold on HealthCare.gov and state-based exchanges must cover the ten federally defined Essential Health Benefits (EHB) categories under ACA §1302(b), but weight-loss drugs are explicitly excluded from the EHB prescription drug benchmark. As a result, carriers individually decide whether to add GLP-1 anti-obesity medications (Wegovy, Zepbound, Saxenda) to formulary — and most marketplace plans either exclude them outright, place them on the highest specialty tier, or wrap them in step therapy and prior authorization. GLP-1s prescribed for FDA-approved non-weight-loss indications (Ozempic, Mounjaro, Rybelsus for type 2 diabetes; Wegovy for cardiovascular risk reduction post-SELECT; Zepbound for obstructive sleep apnea) have a meaningfully higher likelihood of coverage, but every claim still depends on the specific issuer's formulary for the plan year. Always pull the current Summary of Benefits and Coverage (SBC) and the plan's drug list (formulary) before assuming any GLP-1 is covered, and verify with your specific plan and current formulary.

Statutory and structural notes

ACA §1302(b) (42 U.S.C. §18022) defines Essential Health Benefits but does not require coverage of weight-loss medications; HHS benchmark plan rules let states and issuers exclude anti-obesity drugs. ACA §2711 prohibits annual/lifetime dollar limits on EHB, but non-EHB drugs (including most anti-obesity GLP-1s) are not protected. Internal and external appeal rights are guaranteed under ACA §2719 (29 CFR §2590.715-2719), giving members a federally protected pathway to challenge denials regardless of whether the drug is classified as EHB.

Typically considered for coverage

The list below reflects general patterns observed across ACA Marketplace Plansplan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Ozempic when prescribed for type 2 diabetes with documented diagnosis — coverage and tier vary by issuer; verify with your specific plan and current formulary
• Mounjaro when prescribed for type 2 diabetes with documented diagnosis — typically subject to prior authorization; verify with your specific plan and current formulary
• Rybelsus (oral semaglutide) for type 2 diabetes — formulary placement varies widely; verify with your specific plan and current formulary
• Wegovy may be covered by select marketplace plans that have added it for the FDA-approved cardiovascular risk reduction indication (post-SELECT trial, 2024) in adults with established CVD and overweight/obesity; verify with your specific plan and current formulary
• Zepbound may be covered by select marketplace plans for the FDA-approved obstructive sleep apnea indication (2024) in adults with obesity and moderate-to-severe OSA; verify with your specific plan and current formulary
• Saxenda (liraglutide) is rarely on marketplace formularies but occasionally included with prior authorization; verify with your specific plan and current formulary

Typically excluded

• GLP-1s prescribed solely for weight loss on plans that have adopted an anti-obesity drug exclusion (the majority of marketplace plans)
• Off-label use of T2D-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus) for weight loss without a diabetes diagnosis
• Compounded semaglutide or tirzepatide from non-FDA-approved sources — universally excluded by marketplace formularies
• Brand GLP-1s when a preferred alternative is available and step therapy has not been completed
• Quantity exceeding plan-defined limits without medical exception

Prior authorization

Prior authorization is commonly required for GLP-1 medications under ACA Marketplace Plans plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

Under ACA §2719, file an internal appeal within 180 days of denial with a letter of medical necessity citing FDA-approved indication, BMI, comorbidities, and failed prior therapies. If denied, request external review by an independent IRO. Use expedited review (72 hours) when delay risks health. Escalate unresolved denials to your state Department of Insurance.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.